Work

Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM): Efficacy and Safety with 34-Month Median Follow-up

Year: 2024

Type: conference-abstract

Source: Blood

DOI: 10.1182/blood-2024-201080

Authors: Michael R Bishop, Jacalyn Rosenblatt, Binod Dhakal, Noopur Raje, Daniella Cook, Mahmoud R. Gaballa, Estelle Emmanuel-Alejandro, Danielle Nissen, Kamalika Banerjee, Rebecca J Chan, Ana Kostic, Christopher R. Heery, Tim Welliver, David Avigan, Andrzej J Jakubowiak, Matthew Frigault

Institutions: University of Chicago, Beth Israel Deaconess Medical Center, Harvard University, Medical College of Wisconsin, Massachusetts General Hospital, The University of Texas MD Anderson Cancer Center

Language: English

Topic: CAR-T cell therapy research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4405039439

Cites:

Cited by: 12

Related to: 10